Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal
cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several …

5-Fluorouracil (5-FU) has been the mainstay of systemic therapy for colorectal cancer since
its initial development 40 years ago. Efforts to improve the therapeutic index of 5-FU have …

For nearly four decades, 5-fluorouracil (5-FU) has been the mainstay of treatment for
colorectal cancer. Due to the lack of other agents with significant activity, tremendous efforts …

Background Colorectal cancer (CRC) is a disease with high morbidity and mortality rates. 5-
fluorouracil (5-FU) is the first-line recommended drug for chemotherapy in patients with …

Despite more than 30 years of intensive studies on new drugs against advanced colorectal
cancer, the fluoropyrimidines remain the drugs of choice for systemic treatment and for …

PURPOSE: To investigate mechanism-directed regimens in maximizing the efficacy of
fluorouracil (5-FU) in advanced colorected cancer. PATIENTS AND METHODS: Based on …

Colorectal cancer (CRC) is a public health problem. It is the third most common cancer in the
world, with nearly 1.8 million new cases diagnosed in 2018. The only curative treatment is …

Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality.
Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above …

Today, adjuvant 5-fluorouracil based therapy is known to significantly reduce the relapse
rates and the risks of dying from resected colon cancer; chemotherapy approximately …

Purpose Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with
advanced colorectal cancer, but the survival difference between the two treatments is small …